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sUmmARy – The principal iron storage protein is ferritin, which is primarily present in cyto-
plasm. The most common cause of hyperferritinemia is iron overload, which is either primary or 
secondary. Hyperferritinemia is commonly found in patients with chronic kidney disease regardless 
of their hemoglobin level and is often considered to be related to chronic inflammatory status as well 
as malnutrition and neoplasias. We present a case of a kidney transplant patient that developed se-
vere hyperferritinemia associated with liver dysfunction. in our patient, high hyperferritinemia was 
detected a year after transplantation, when she had no signs of inflammation. malignancies, chronic 
viral hepatitis, and chronic inflammatory disease were also excluded as the causes of hyperferritine-
mia. since high serum ferritin levels were combined with increased transferrin saturation and mildly 
elevated plasma iron concentrations, we presume that the most probable cause of hyperferritinemia 
in our patient was iron overload.
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Introduction 
The principal iron storage protein is ferritin, which 
is primarily present in cytoplasm. it is composed of 
24 subunits that are of two different types, heavy and 
light chains, mW 18000 da1,2. The main role of fer-
ritin is the regulation of iron metabolism either for 
the synthesis of hemoglobin or for the oxidation of 
highly toxic fe (ii) into fe (iii)3. ferritin synthesis 
is regulated by intracellular iron concentration2,4. The 
most common cause of hyperferritinemia is iron over-
load, which is either primary or secondary. Heredi-
tary hemochromatosis (HH) is the most often cause 
of primary iron overload. HH is a genetically hetero-
geneous disease that is caused by mutations located 
on the Hfe gene; the most common ones are termed 
C282y and H63d5. 
secondary iron overload results from excessive 
intake of iron from multiple blood transfusions, par-
enteral iron administration, dietary intake, or iron 
supplements. it can also occur in patients who have 
chronic disorders of erythropoiesis or hemolytic ane-
mias5.
Hyperferritinemia in the absence of iron overload 
may occur in certain liver diseases such as chronic vi-
ral hepatitis6, during episodes of inflammation, since 
ferritin is an acute phase reactant7, and in inflam-
matory diseases (e.g., rheumatoid arthritis and he-
mophagocytic lymphohistiocytosis). Obesity and ma-
lignancy can also raise plasma ferritin concentration8. 
Hyperferritinemia is commonly found in patients 
with chronic kidney disease (CKd) regardless of their 
hemoglobin level, and is often considered to be related 
to chronic inflammatory status as well as malnutrition 
and neoplasias9. patients with CKd under different 
forms of renal replacement therapy are also at a risk of 
developing secondary iron overload for two reasons. 
first, before erythropoietin therapy for correction 
of renal anemia they frequently receive blood trans-
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fusions. second, from the introduction of treatment 
with erythropoiesis-stimulating agents these patients 
routinely receive iron supplementation for successful 
treatment of renal anemia10.
We present a case of a kidney transplant patient 
that developed severe hyperferritinemia associated 
with liver dysfunction.
Case Report
A 55-year-old woman with end-stage renal disease 
due to polycystic kidney disease, who had been treated 
with hemodialysis (Hd) for 11 years, received a renal 
allograft from a deceased donor at age 51. As part of 
her Hd treatment, she had been administered iron 
i.v. during a 6.5-year period. On one occasion, she re-
ceived blood transfusion. laboratory findings at the 
time of kidney transplantation showed normal liver 
function (Ast 20 U/l, Alt 39 U/l). The kidney 
transplantation was performed and she was treated 
with cyclosporine, mycophenolate mofetil and pred-
nisone.
Graft function after transplantation was normal 
and remained stable throughout the 4-year follow-
up period (mean creatinine value 93.3±5.0 μg/l). 
no episodes of graft rejection were noted during that 
time. On day 5 of transplantation, an increase in liver 
enzymes (Alt 67 U/l, Ast 29 U/l, GGt 32 U/l) 
was noted, reaching maximum on day 7 of transplan-
tation, and remained increased throughout the follow-
up period (fig. 1). A year after transplantation, severe 
hyperferritinemia (ferritin 4195 μg/l; normal range 
for female 20-120 μg/l) combined with transferrin 
saturation (tsAt) of 75% and a mild increase in se-
rum iron and tiBC (serum fe 39 μmol/l, tiBC 52 
μmol/l) was detected. during the next three years, 
ferritin levels and tsAt remained high (mean ferritin 
3399.6±19.6 μg/l, mean tsAt 74.6±1.8%, mean se-
rum fe 34.5±1.6 μg/l, mean tiBC 46.3±1.8 μmol/l) 
(fig. 1). Therapeutic venepunctures were started two 
years after detection of hyperferritinemia. 
Ultrasonography (Us) of the abdomen showed 
enlarged liver with multiple cystic formations. Ab-
dominal multislice computed tomography (msCt) 
showed multiple cystic formations, increased paren-
chymal density and an accessory spleen. 
Bone marrow aspiration showed increased white 
to red cell line ratio (5.5:1). erythropoiesis was slight-
ly depressed, mature, with low percentage of megalo-
blastoid cells. Cytomorphological appearance of pe-
ripheral blood smear was within the normal range.
Genetic analysis for hereditary hemochromatosis 
(C282y, H63d and s65C) was negative. Both hepa-
titis B virus surface antigen and C virus antibody were 
negative, as well as cytomegalovirus (CmV) antigen-
emia. Autoimmune and metabolic disease, tumors, 
and hemolytic anemia were excluded as the reasons of 
hepatic lesion. due to multiple liver cysts, liver biopsy 
was not performed. 
Discussion
it is well known that liver impairment may occur 
after kidney transplantation11. The possible etiolo-
gies for liver dysfunction after renal transplantation 
include drug toxicity (immunosuppressive and non-
immunosuppressive agents)12,13, viral activity (hepatits 
B, hepatitis C, CmV and other hepatotoxic viruses), 
vascular lesion and sepsis12. Our patient showed signs 
of severe hyperferritinemia and early liver impair-
ment after transplantation. since she had cystic for-
mations in the liver prior to transplantation as part 
of her primary renal disease (polycystosis) and normal 
levels of liver enzymes, we presume that the liver im-
pairment was not of that source. The most probable 
cause of liver impairment was cyclosporine toxicity. 
Cyclosporine and prednisone therapy have been as-
sociated with hepatotoxic episodes that were usually 
self-limited, and generally occurred during the very 
Fig. 1. Changes in serum liver enzyme levels (triangles in-
dicate levels of ALT, squares levels of AST, and circles levels 
of GGT); serum ferritin concentrations during the follow-up 
period are shown by rhombi. Black arrow indicates the begin-
ning of gastroenterologic involvement. Grey arrows show the 
time of therapeutic bloodletting treatment.
Days after transplantation
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early posttransplant period13. Hyperferritinemia may 
be found in patients with CKd regardless of their he-
moglobin level and is often considered to be related to 
chronic inflammation, malnutrition and neoplasias9. 
in our patient, high hyperferritinemia was detected a 
year after transplantation, without signs of inflamma-
tion. during the follow-up period, neoplasias, chronic 
viral hepatitis and chronic inflammatory disease were 
also excluded as the reasons of hyperferritinemia. 
since high serum ferritin levels were combined with 
increased tsAt and mildly elevated plasma iron con-
centrations, we presume that the most probable cause 
of hyperferritinemia in our patient was iron overload. 
in the study of iron overload in kidney transplanta-
tion, it was shown that about 36% of such patients also 
had HFE mutations10. in our case, HFE mutations for 
hereditary hemochromatosis were negative, and pa-
rameters showing iron overload and liver impairment 
remained increased throughout the follow-up period, 
unlike the study group, thus indicating that our patient 
was not in this class. Alternatively, in a case report14, 
liver dysfunction was assigned to hemosiderosis in a 
renal transplant recipient, due to blood transfusions 
and iron replacement therapy prior to kidney trans-
plantation; our patient might be a candidate for such 
assignment, however, liver biopsy to confirm this pre-
sumption was contraindicated in our patient. 
This case is presented to emphasize the importance 
of iron store assessment in patients with chronic kid-
ney disease prior to initiating therapy. Both tsAt 
and serum ferritin should be considered. in hemodi-
alysis patients, absolute iron deficiency is considered 
when tsAt is <20% and serum ferritin concentration 
is less than 200 μg/l. functional deficiency is associ-
ated with tsAt ≤20% and serum ferritin higher than 
200 μg/l, and is characterized by the presence of ad-
equate iron stores but inability to sufficiently mobilize 
iron when erythropoiesis is stimulated by an erythro-
poietic stimulating agent15. in both cases, a sufficient 
amount of iron to correct iron deficiency should be 
administered16, but the administration of intravenous 
iron should be individually assessed in patients with 
ferritin levels above 500 μg/l and anemia. in patients 
with serum concentration above 500 μg/l and/or 
tsAt above 50%, iron should be administered with 
caution due to the probability of iron overload. iron 
therapy and erythropoietic stimulating agents should 
be administered in hemodialysis patients to achieve 
and maintain target hemoglobin levels between 110 
and 120 g/l in accordance with the K/dOQi guide-
lines16.
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sažetak
HipeRfeRitinemiJA U BOlesniKA s pResAtKOm BUBReGA 
V. Furić-Čunko, N. Bašić-Jukić, I. Jurić i P. Kes
feritin je glavni protein za skladištenje željeza i prvenstveno je prisutan u citoplazmi. najčešći uzrok hiperferitine-
mije je preopterećenje željezom, koje može biti primarno ili sekundarno. Hiperferitinemija se često nalazi u bolesnika s 
kroničnom bubrežnom bolesti bez obzira na razinu njihovog hemoglobina i smatra se da je povezana s kroničnom upa-
lom, pothranjenošću i novotvorinama. prikazujemo slučaj bolesnice s transplantiranim bubregom u koje se razvila teška 
hiperferitinemija povezana s jetrenom disfunkcijom. U naše bolesnice hiperferitinemija je otkrivena godinu dana nakon 
transplantacije, kada u nje nije bilo znakova upale. Zloćudne bolesti, kronični virusni hepatits i kronična upalna bolest 
su također isključeni kao uzroci hiperferitinemije. Kako je visoka koncentracija feritina bila udružena s povišenom zasi-
ćenošću transferina i umjereno povišenom koncentracijom željeza u plazmi, pretpostavljamo da je najvjerojatniji uzrok 
hiperferitinemije bilo preopterećenje željezom. 
Ključne riječi: Transplantacija bubrega; Bubrežna insuficijencija, kronična; Hiperferitinemija; Željezo, opterećenje; Prikaz 
slučaja
